Cocrystal Pharma, Inc. (COCP)
NASDAQ: COCP · Real-Time Price · USD
1.020
+0.010 (0.99%)
At close: Jun 26, 2026, 4:00 PM EDT
1.000
-0.020 (-1.97%)
After-hours: Jun 26, 2026, 7:50 PM EDT
Cocrystal Pharma Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Cocrystal Pharma stock has a target of 10, which predicts an increase of 880.39% from the current stock price of 1.02.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 27, 2026.
Analyst Ratings
The average analyst rating for Cocrystal Pharma stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Feb '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Noble Financial | Noble Financial | Buy Reiterates $10 | Buy | Reiterates | $10 | +880.39% | May 27, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.69
from -0.78
EPS Next Year
-0.64
from -0.69
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | n/a | |
| Avg | n/a | n/a | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.61 | -0.64 | |
| Avg | -0.69 | -0.64 | |
| Low | -0.76 | -0.64 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.